Skip to main content
. Author manuscript; available in PMC: 2008 Jul 2.
Published in final edited form as: Eur J Pharmacol. 2007 Mar 19;566(1-3):117–119. doi: 10.1016/j.ejphar.2007.03.007

Fig. 2.

Fig. 2

The BK channel opener isopimaric acid and the endocannabinoid anandamide synergistically inhibit pain behavior. A and C: Dose dependent inhibition of (A) phase I (0-15 min.) or (C) phase II (15-45 min) formalin-evoked pain behavior in Swiss mice by intraplantarly administered isopimaric acid (IPA, 1-100 μg/paw) or vehicle (V). B and D: Effects of anandamide (AEA, 0.1 μg/paw) alone or together with isopimaric acid (IPA, 0.1 μg/paw) on (B) phase I or (D) phase II formalin-evoked pain behavior in Swiss mice (n = 6) ** P < 0.01 vs. V.

HHS Vulnerability Disclosure